Cancer Research Communications

Displaying 1 - 10 of 10
Heath, H., Yoo, J. Y., Akter, S., Jain, A., Sharma, V., McGee, H., Soliman, A., Mahmoud, A. M., Matthews, A. K., Winn, R. A., Madak-Erdogan, Z., & Kim, S. J. (2024). The Effect of Exposure to Neighborhood Violence on Glucocorticoid Receptor Signaling in Lung Tumors. Cancer Research Communications, 4(7), 1643–1654. https://doi.org/10.1158/2767-9764.crc-24-0032
Publication Date
Columbia Affiliation
Rustgi, N., Wu, S., Samec, T., Walker, P., Xiu, J., Lou, E., Goel, S., Saeed, A., & Moy, R. H. (2024). Molecular Landscape and Clinical Implication of CCNE1-amplified Esophagogastric Cancer. Cancer Research Communications, 4(6), 1399–1409. https://doi.org/10.1158/2767-9764.crc-23-0496
Publication Date
Yarchoan, M., Powderly, J. D., Bastos, B. R., Karasic, T. B., Crysler, O. V., Munster, P. N., McKean, M. A., Emens, L. A., Saenger, Y. M., Ged, Y., Stagg, R., Smith, S., Whiting, C. C., Moon, A., Prasit, P., Jenkins, Y., Standifer, N., Dubensky, T. W., Whiting, S. H., & Ulahannan, S. V. (2024). First-in-human Phase I Trial of TPST-1120, an Inhibitor of PPARα, as Monotherapy or in Combination with Nivolumab, in Patients with Advanced Solid Tumors. Cancer Research Communications, 4(4), 1100–1110. https://doi.org/10.1158/2767-9764.crc-24-0082
Publication Date
Abou-Alfa, G. K., Geyer, S. M., Nixon, A. B., Innocenti, F., Shi, Q., Kumthekar, P., Jacobson, S., El Dika, I., Yaqubie, A., Lopez, J., Huang, B., Tang, Y.-W., Wen, Y., Schwartz, L. H., El-Khoueiry, A. B., Knox, J. J., Rajdev, L., Bertagnolli, M. M., Meyerhardt, J. A., … Venook, A. P. (2024). CALGB 80802 (Alliance): Impact of Sorafenib with and without Doxorubicin on Hepatitis C Infection in Patients with Advanced Hepatocellular Carcinoma. Cancer Research Communications, 4(3), 682–690. https://doi.org/10.1158/2767-9764.crc-22-0516
Publication Date
Ambrosini, G., Natale, C. A., Musi, E., Garyantes, T., & Schwartz, G. K. (2023). The GPER Agonist LNS8801 Induces Mitotic Arrest and Apoptosis in Uveal Melanoma Cells. Cancer Research Communications, 3(4), 540–547. https://doi.org/10.1158/2767-9764.crc-22-0399
Publication Date
Dermawan, J. K. T., Nafa, K., Mohanty, A., Xu, Y., Rijo, I., Casanova, J., Villafania, L., Benhamida, J., Kelly, C. M., Tap, W. D., Boland, P. J., Fabbri, N., Healey, J. H., Ladanyi, M., Lu, C., & Hameed, M. (2023). Distinct IDH1/2-associated Methylation Profile and Enrichment ofTP53andTERTMutations Distinguish Dedifferentiated Chondrosarcoma from Conventional Chondrosarcoma. Cancer Research Communications, 3(3), 431–443. https://doi.org/10.1158/2767-9764.crc-22-0397
Publication Date
Gong, Y.-Y., Shao, H., Li, Y., Brafford, P., Stine, Z. E., Sun, J., Felsher, D. W., Orange, J. S., Albelda, S. M., & Dang, C. V. (2022). Na+/H+-exchanger 1 Enhances Antitumor Activity of Engineered NK-92 Natural Killer Cells. Cancer Research Communications, 2(8), 842–856. https://doi.org/10.1158/2767-9764.crc-22-0270
Publication Date